Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.
Anichini A, Molla A, Nicolini G, Perotti VE, Sgambelluri F, Covre A, Fazio C, Lofiego MF, Di Giacomo AM, Coral S, Manca A, Sini MC, Pisano M, Noviello T, Caruso F, Brich S, Pruneri G, Maurichi A, Santinami M, Ceccarelli M, Palmieri G, Maio M, Mortarini R; EPigenetic Immune-oncology Consortium AIRC (EPICA) investigators. Anichini A, et al. Among authors: fazio c. J Exp Clin Cancer Res. 2022 Nov 17;41(1):325. doi: 10.1186/s13046-022-02529-5. J Exp Clin Cancer Res. 2022. PMID: 36397155 Free PMC article.
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C, Giovannoni L, Elia G, Neri D, Maio M, Santinami M. Danielli R, et al. Among authors: fazio c. Cancer Immunol Immunother. 2015 Aug;64(8):999-1009. doi: 10.1007/s00262-015-1704-6. Epub 2015 May 14. Cancer Immunol Immunother. 2015. PMID: 25971540 Free PMC article. Clinical Trial.
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.
Di Giacomo AM, Covre A, Finotello F, Rieder D, Danielli R, Sigalotti L, Giannarelli D, Petitprez F, Lacroix L, Valente M, Cutaia O, Fazio C, Amato G, Lazzeri A, Monterisi S, Miracco C, Coral S, Anichini A, Bock C, Nemc A, Oganesian A, Lowder J, Azab M, Fridman WH, Sautès-Fridman C, Trajanoski Z, Maio M. Di Giacomo AM, et al. Among authors: fazio c. Clin Cancer Res. 2019 Dec 15;25(24):7351-7362. doi: 10.1158/1078-0432.CCR-19-1335. Epub 2019 Sep 17. Clin Cancer Res. 2019. PMID: 31530631 Clinical Trial.
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy.
Lofiego MF, Cannito S, Fazio C, Piazzini F, Cutaia O, Solmonese L, Marzani F, Chiarucci C, Di Giacomo AM, Calabrò L, Coral S, Maio M, Covre A, On Behalf Of The EPigenetic Immune-Oncology Consortium Airc Epica Investigators. Lofiego MF, et al. Among authors: fazio c. Epigenomes. 2021 Dec 14;5(4):27. doi: 10.3390/epigenomes5040027. Epigenomes. 2021. PMID: 34968251 Free PMC article.
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5-7, 2017.
Maio M, Lofiego MF, Fazio C, Cannito S, Chiarucci C, Giacobini G, Valente M, Tunici P, Covre A, Russo V. Maio M, et al. Among authors: fazio c. Cancer Immunol Immunother. 2019 Jan;68(1):151-158. doi: 10.1007/s00262-018-2222-0. Epub 2018 Aug 9. Cancer Immunol Immunother. 2019. PMID: 30094463 Free PMC article. No abstract available.
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
Calabrò L, Rossi G, Morra A, Rosati C, Cutaia O, Daffinà MG, Altomonte M, Di Giacomo AM, Casula M, Fazio C, Palmieri G, Giannarelli D, Covre A, Maio M. Calabrò L, et al. Among authors: fazio c. Lancet Respir Med. 2021 Sep;9(9):969-976. doi: 10.1016/S2213-2600(21)00043-6. Epub 2021 Apr 9. Lancet Respir Med. 2021. PMID: 33844995 Free PMC article.
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, Biagioli M, Altomonte M, Maio M. Di Giacomo AM, et al. Among authors: fazio c. Cancer Immunol Immunother. 2013 Jun;62(6):1021-8. doi: 10.1007/s00262-013-1418-6. Epub 2013 Apr 17. Cancer Immunol Immunother. 2013. PMID: 23591982 Free PMC article.
243 results